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Prognostic Significance of Left Atrial Volume
Dilatation in Patients with Hypertrophic
Cardiomyopathy
Maria-Angela Losi, MD, Sandro Betocchi, MD,* Giovanni Barbati, MD,
Valentina Parisi, MD, Carlo-Gabriele Tocchetti, MD, Fabio Pastore, MD,
Teresa Migliore, MD, Carla Contaldi, MD, Armando Caputi, MD, Rosalba Romano, MD,
and Massimo Chiariello, MD, Naples, Italy
To evaluate the prognostic role of left atrial (LA) volume in hypertrophic cardiomyopathy (HCM), LA volume was
measured at baseline and during follow-up in 140 patients with HCM. Unfavorable outcome, defined as
occurrence of sudden death, heart transplantation, or invasive reduction of obstruction, developed in 16 patients.
In patients with enlarged LA volume (!27 mL/m2), there was an increased risk for unfavorable outcome (P "
.0152). Patients with normal LA volume at baseline in whom volume increased more than 3 mL per year (fast
dilating LA volume) had a worse prognosis than patients with normal and stable volume (P# .001) and similar to
patients with dilated LA volume at baseline (P " not significant). LA volume dilated at baseline, fast dilating
LA volume, and New York Heart Association functional class were independent predictors of unfavorable
outcome development (odds ratio: 11.453; P " .021, P " 2.019, P " .020, respectively). The assessment of
LA volume at baseline and during follow-up adds information regarding prognosis in patients with HCM. (J Am
Soc Echocardiogr 2009;22:76-81.)
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Hypertrophic cardiomyopathy (HCM) is a primary myocardial dis-
ease characterized by left ventricular hypertrophy in the absence of
causes capable of inducing hypertrophy.1–4 The presentation and
clinical course of the disease are extremely variable: patients can be
asymptomatic throughout life, die suddenly, or develop an array of
symptoms, ultimately leading to atrial fibrillation (AF), stroke, or heart
failure.1–5 The identification of patients at risk of unfavorable out-
come is one of the most important issues of the disease.6–9
Left atrial (LA) volume, measured by 2-dimensional echocardiog-
raphy, is the most accurate measure of LA size10,11 because little
variations in the linear dimension are often associated with large
variation in volume as the result of asymmetric LA remodeling.10–13
In HCM, increased LA linear dimension is a strong predictor of poor
outcome,14 moreover, increased LA volume predicts the develop-
ment of AF15,16 and it is related to exercise capacity17 even in
patients without obstruction at rest or during provocation.18 There is
evidence of increased LA volume in patients with a history of
cardiovascular morbidity.19 However, the prognostic role of LA
volume in patients with HCM is not known. Thus, this study was
undertaken to investigate the prognostic role of LA volume in
patients with HCM.
MATERIALS AND METHODS
We considered 262 patients with HCM who were consecutively
enrolled and followed up at the Federico II University School of
Medicine. The diagnosis of HCM was made on the basis of M-mode
and 2-dimensional echocardiographic evidence of a hypertrophied,
nondilated left ventricle without any cardiac or systemic cause capa-
ble of inducing hypertrophy.1–4 The initial evaluation was defined as
the first visit to the Federico II University School of Medicine. Patients
were excluded from the study if they 1) had been followed up less
than 1 year (66 patients); 2) had no high-quality echocardiograms (14
patients); 3) had end-stage HCM (6 patients); 4) had previous
myotomy-myectomy (4 patients); 5) were in AF or had history of AF
at the time of the enrollment (20 patients); or 6) were aged less than
18 years at the time of enrollment (12 patients). This exclusion was
done to attenuate the influence of body size variations during growth
on the measure of LA volume indexed to body surface area (see
below). Thus, the final population consisted of 140 patients, 87 men
(mean age 40$ 15 years, range 18–83 years). Follow-up was 5$ 3
years (range 1–15 years). Symptoms were assessed at the time of
enrollment in each patient and eventually during follow-up.
Echocardiography
Echocardiography was performed using Hewlett Packard imaging
systems (Sonos 1000 from 1990 to 2000 and Sonos 5500 thereafter,
Andover, MA) with 2.5 and harmonic 3.5 MHz variables frequency
transducers. Left ventricular end-diastolic diameter was measured just
below the mitral valve leaflets and indexed to the body surface
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area.20 LA volume was computed from the apical 4-chamber view by
tracing the outline of atrial endocardium at end systole.12 The volume
was computed by using the method of discs12,18 and normalized to
body surface area, defined as LA volume index (LAVi). LAVi greater
than 27mL/m2 was considered dilated.21 LAVi was also measured at
the end of follow-up, defined as the last recorded value in patients
who did not develop events or the last recorded value before events
developed. Dilatation rate was thus based on the first and last
echocardiographic studies. As an estimate of the degree of left
ventricular hypertrophy, maximal wall thickness measured at any
level in the left ventricular walls was obtained.3
Color Doppler flow imaging was used for semiquantitative assess-
ment of mitral regurgitation.22 Left ventricular outflow tract obstruc-
tion (LVOTG) was recorded at rest by a 1.9 MHz nonimaging
transducer using the simplified Bernoulli equation (P" 4v2, where P
is pressure and v is flow velocity). Particular care was taken to avoid
contamination of the left ventricular outflow waveform by the mitral
regurgitation jet.23 All echocardiographic measurements were ob-
tained by averaging 3 consecutive cardiac cycles.
Clinical End Points and Definitions
Clinical information was gathered during return visits. The clinical
end point considered in this study was a combined end point that
included sudden and unexpected death, including resuscitated car-
diac arrest, the development of severe symptoms (ie, New York Heart
Association [NYHA] functional class III or IV) requiring invasive
correction of LVOTG (septal ablation or myotomy-myectomy), or
heart transplantation. AF was not considered as an end point because
the impact of LA dilatation on the development of such arrhythmias
has been already demonstrated.15,16 Patients were treated as clini-
cally indicated during follow-up; as a consequence, treatment was not
standardized and the present study does not address the effects of
treatment on the natural history of the disease.
Statistics
All statistical calculations were performed using SPSS for Windows,
release 12 (SPSS, Chicago, IL). Paired and unpaired t test were used
when appropriate. Chi-square analysis was used to test differences in
categoric variables. The cumulative risk of development of events was
assessed with the Kaplan–Meier method. Odds ratio (OR) and 95%
confidence intervals (CIs) were calculated by using univariate and
multivariate Cox proportional-hazard regression models; all variables
but LA dilation at baseline or during follow-up were continuous; LA
dilation at baseline or during follow-up was coded 0 for patients with
normal LAVi who did not dilate and 1 for all the others. The
repeatability coefficient was determined as 1.96% standard deviation
of the absolute value of the differences.24 A value of P # .05 was
considered to be significant.
RESULTS
Patient Population
Baseline mean LAVi was 29.2 $ 11.8 mL/m2. Patients were then
divided into 2 subgroups according to their LAVi:! 27 mL/m2 in 72
patients and dilated at baseline (ie, ! 27 mL/m2) in 68 patients. The
demographic characteristics of the 2 subgroups are reported in Table
1. During follow-up, there were 16 events: seven patients died
suddenly, of whom 1 had a resuscitated cardiac arrest; 1 patient
developed heart failure requiring heart transplantation; and 8 patients
underwent invasive treatment of LVOTG because of refractory
severe symptoms (myotomy-myectomy in 6 and septal ablation in 2).
LA Volume Measurement Reproducibility
Intraobserver variability. Test–retest variability (ie, 1 blinded ob-
server measured LA volume on 2 sets of recorded images acquired
independently and at different times) was tested in 19 consecutive
subjects not included in the patient population (4 with valvular heart
disease, 10 with coronary artery disease, and 5 without heart disease).
Two echocardiograms were performed in each patient; the time
elapsed between them was 24 to 36 hours. Patients’ identities were
blinded for the observer to measure both studies independently. The
repeatability coefficient was 2.8 mL. Thus, in our population, a
dilating LA volume was considered when volume increased " 3 mL
per year.
Prognostic Role of LA Volume at Baseline
The risk of unfavorable outcomewas significantly greater in the group
with a dilated LAVi (Figure 1). Accordingly, the negative predictive
value of LA dilatation was 93%. In contrast, its positive predictive
value was low (16%).
Outcome and Obstruction
We further analyzed outcome by excluding patients with significant
obstruction at rest and found that a LAVi greater than 27 mL/m2 in
patients without obstruction still differentiated patients with and
without events (P " .0054) (Figure 3). A similar analysis was not
performed in the subgroup of patients with obstruction at rest
because of the small number of such patients, preventing us from
gaining significant information on survival. Survival was still signifi-
Table 1 Demographic characteristics of patients divided into 2 subgroups according to LAVi values at baseline
Clinical and echocardiographic findings at baseline LAVi < 27 mL/m2 (72) LAVi > 27 mL/m2 (68) P
Age (y) 34.1 $ 14.4 45.7 $ 13.6 #.001
NHYA functional class 1.32 $ 0.55 1.71 $ 0.69 #.001
LA diameter (mm) 38.2 $ 4.1 47.2 $ 4.8 #.001
LAVi (mL/m2) 20.5 $ 3.5 38.3 $ 10.4 #.001
LV end-diastolic diameter index (mm/m2) 24.5 $ 2.9 25.1 $ 3.2 NS
LV fractional shortening (%) 44.8 $ 8.5 46.6 $ 9.0 NS
Maximal wall thickness (mm) 20.2 $ 5.5 22.2 $ 5.1 .033
LV outflow tract obstruction (mm Hg) 9.4 $ 22.4 25.7 $ 30.7 #.001
Significant LV outflow tract obstruction ("30 mm Hg) 5 25 #.001
Mitral regurgitation (score) 0.43 $ 0.75 0.93 $ 1.03 .001
LA, Left atrial; LAVi, left atrial volume index; LV, left ventricular; NYHA, New York Heart Association.
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cantly different when patients with normal LAVi without enlarge-
ment during follow-up were compared with patients with enlarge-
ment during follow-up or at entry, and the end point included was
only heart transplantation and sudden death (P " .008) (Figure 4).
Prognostic Role of LA Dilatation Development
We tested the hypothesis that patients with a normal LAVi (ie, !27
mL/m2) at entry who showed an increase in volume per year equal
to or greater than our coefficient of reproducibility (ie, 3 mL) had a
worse prognosis than patients with normal and stable LA volume
throughout follow-up. There were 72 patients with normal LAVi at
baseline (45 men with a mean age 34 $ 14 years, range 18–79
years). There was a decrease, no change, or an increase in volume less
than 3 mL per year (stable LA volume group) in 58 of these patients,
whereas the change in volume was " 3 mL per year in 14 of these
patients (fast dilating LA volume group).
Patients in the dilating group had a worse outcome than patients in
the stable group (P # .001) and similar to that of patients with a
dilated LAVi at baseline (P" not significant) (Figure 2). The negative
predictive value for unfavorable outcome of a normal and stable LA
volume was 98%; however, the positive predictive value was 18%.
By Cox regression univariate analysis, we identified predictors of
unfavorable outcome (Table 2). Cox regression multivariate analysis
was performed using variables that were significant by univariate Cox
regression analysis, with in turn one of the LA variables (LAVi or the
categoric variable LA dilation at baseline or during follow-up). When
LAVi at baseline was used, NYHA functional class was the only
predictor of unfavorable outcome (OR 2.812; 95% CI, 1.614–
4.899); when the categoric variable LA dilation at baseline or during
follow-up was used, NYHA functional class and this variable were
independent predictors of unfavorable outcome (NYHA functional
class: OR: 2.019; 95% CI, 1.115–3.656, P " .020; LA dilation at
baseline or during follow-up: OR: 11.453; 95% CI, 1.444–90.848,
P " .021). In the multivariate approach, neither mitral regurgitation
nor LVOTG were predictors of unfavorable outcome.
DISCUSSION
Our study demonstrates that an enlarged left atrium or a fast dilating
LA volume represent risk factors of unfavorable outcome in patients
with HCM (Figures 1 and 2). Moreover, our data show that NYHA
class and an LA volume dilated at baseline or with a fast dilation
during follow-up are independent strong predictors of unfavorable
outcome in patients with HCM. Patients with nondilated LA volume,
who do not dilate during follow-up, are expected to have a good
prognosis in view of the high negative predictive power, and can be
reassured.
Outcome and HCM
HCM is a complex primary myocardial disease with a diverse clinical
presentation that includes a benign or stable clinical course over many
years, sudden death, and progressive, invalidating symptoms requir-
ing therapeutic intervention. Sudden death often occurs in younger
patients, although it is present in all decades of life.25 In the present
study, which was performed in an adult population with HCM, the
annual incidence of sudden death was 1%, and the incidence of
development of severe symptoms requiring invasive treatment (re-
duction of LVOTG or heart transplantation) was 1.2%. Thus, the
Figure 2 Probability of freedom from unfavorable outcome of
patients with dilated LAVi at baseline (!27 mL/m2) and of
patients with LAVi ! 27 mL/m2, with stable (ie, LA volume
increase #3 mL/y) or fast dilating LA volume throughout
follow-up (ie, LA volume increase " 3 mL/y). Prognosis was
significantly poorer in patients with dilated LAVi at baseline
(!27 mL/m2) and in patients with nondilated, fast dilating LAVi,
as opposed to patients with nondilated, stable LAVi (P # .001
for both). LA, Left atrial.
Figure 1 Probability of freedom from unfavorable outcome
according to LAVi values at baseline (cut point: 27 mL/m2).
LAVi, Left atrial volume index.
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incidence of the combined end point considered in the present study
was 2.2% per year; these results are similar to those of previous
reports7,25 performed in larger populations with HCM. The identifi-
cation of patients at risk of sudden death and progressive symptoms
requiring therapeutic intervention is still a challenge.6–9
Outcome and LA Dilatation
In a study by Nistri and coworkers,14 a marked increase in LA linear
dimension was predictive of long-term outcome independently of
coexistent AF or LVOTG, whereas there was no relationship be-
tween the occurrence of sudden death and LA linear dimensions.
Our data complement Nistri et al’s in that LA size is a determinant of
prognosis in HCM. In contrast with their study, our study showed that
LA linear dimension was not a predictor of unfavorable outcome by
Cox univariate analysis (Table 2), perhaps because their population
was taken from a Register and thus larger. This implies that the
prognostic power of LA linear dimension is lower than that of LA
volume and suggests that LA volume may be a more reliable
predictor of prognosis in the individual patient.
It has been shown that LA volume provides a more accurate
measure of LA size than conventional M-mode LA dimension in that
little variation in diameter may result in large variation of LA vol-
ume.10–13 In patients with HCM, 2 studies, one from our group15
and one from Tani et al,16 demonstrated that LA volume predicts the
development of AF. In the present study, patients with LAVi dilation
at baseline were older, had a higher degree of LVOTG and mitral
regurgitation, and were more symptomatic in terms of NYHA class
(Table 1). In the majority of patients with obstructive HCM, mitral
valve regurgitation is a consequence of LVOTG.26 Moreover, dia-
stolic dysfunction is common in HCM regardless of obstruction27,28
and influences LAVi. Thus, in HCM LA volume may serve as a
marker of the severity and duration of LVOTG and diastolic dysfunc-
tion.17–19,29 This is confirmed in our population, in that patients with
a dilated LAVi at baseline had different clinical and echocardio-
graphic characteristics (Table 1). Furthermore, this concept may
explain why patients with a dilated LAVi have a worse prognosis in
our study (Figure 1). In patients with HCM, LAVi is increased in
patients with a history of cardiovascular morbidity19 and is related to
exercise capacity;17 this holds true in patients without obstruction at
rest or during provocation.18 Thus, LA volume represents a marker of
the disease severity and may help in the stratification of risk in
patients with HCM.
Moreover, our study is the first to demonstrate the importance of
LA volume measurement throughout follow-up. We found that in
patients with a normal LA volume at baseline and an increase in
volume of at least 3 mL per year, prognosis was worse than in patients
with stable LA volume throughout follow-up and similar to that of
patients with dilated LAVi at baseline (Figure 2). The negative
predictive values for unfavorable outcome of a normal and stable LA
volume was high: 98%. Although this result is of interest, it must be
underscored that for other clinical risk factors in patients with HCM,
our findings also show a low positive predictive value for events:
18%.
Outcome and Obstruction
We performed a Kaplan–Meier analysis that showed no statistical
differences between patients with and without obstruction (P " .1).
We acknowledge that the number of patients with obstruction in our
population (30) is too small to affirm the negative impact of obstruc-
Figure 3 Probability of freedom from unfavorable outcome
according to LAVi values at baseline (cut point: 27 mL/m2) in
patients without a significant (ie, "30 mm Hg) LVOTG at
baseline. LVOTG, Left ventricular outflow tract obstruction;
LAVi, left atrial volume index.
Figure 4 Probability of freedom from unfavorable outcome by
excluding as an end point the invasive or surgical reduction of
obstruction throughout follow-up. Prognosis was significantly
poorer in patients with dilated LAVi at baseline (!27 mlL/m2)
and in patients with nondilated, fast dilating LAVi, as opposed
to patients with nondilated, stable LAVi (P " .0008). LA, Left
atrial.
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tion on outcome, which has been strongly demonstrated in a large
series of patients (!1000).7 Nevertheless, we further analyzed out-
come by excluding patients with significant obstruction at rest and
found that in patients without obstruction a LAVi greater than 27
mL/m2 still differentiated patients with and without events (P "
.0054) (Figure 3); however, 3 patients without significant obstruction
(gradients of 14, 23 and 25 mm Hg at entry) developed significant
obstruction during follow-up and required myotomy-myectomy sur-
gery. Finally, to exclude any potential influence of obstruction, we
evaluated outcome by excluding as an end point the invasive or
surgical reduction of obstruction throughout follow-up (ie, only heart
transplantation and sudden death were considered unfavorable out-
comes). We found that survival was still significantly different when
patients with normal LAVi without enlargement during follow-up
were compared with patients with enlarged LAVi during follow-up or
at entry (P " .008) (Figure 4).
LIMITATIONS
Although the biplanar measurement of LA volume is recommended
because of the retrospective nature of our work, we used the single
plane method. We acknowledge that this is a limitation; however, the
reproducibility of our measurement was excellent, indicating that this
measure may be used in large population of patients. Moreover,
Lester et al10 demonstrated that the single and biplanar methods are
closely correlated over a wide range of LA sizes.
Moreover, we calculated an annualized rate of LA dilation from
first to last echocardiogram; to exclude fluctuations in measurement,
we selected a cutoff value of LAVi increase larger than the intrinsic
error. We do not imply, however, that this dilatation rate was
consistent throughout follow-up.
CONCLUSIONS
We demonstrated that a dilated LA volume at baseline and a fast
dilating LA volume during follow-up, together with NYHA functional
class, have an independent predictive value for unfavorable outcome
development; in other words, asymptomatic patients in whom LA
volume is not dilated at baseline and does not dilate during follow-up
are expected to have a good prognosis. Thus, both NYHA functional
class and LA volume are robust clinical markers of disease severity.
We suggest that asymptomatic patients with LAVi less than 27
mL/m2 at baseline and an increase in volume less than 3 mL per year
throughout follow-upmay be reassured about their risk of developing
events; in contrast, because of the low positive predictive value,
patients with a dilated or dilating left atrium should be clinically
monitored.
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